We have investigated the value of both conventional and quan- apy are shown in Table 1 . Mean age was 56 years (range,
received treatment prior to evaluation (Table 1) . Two patients underwent allogeneic bone marrow transplantation (Nos 2 and 4) and patient No. 6 underwent a matched unrelated alloIntroduction geneic BMT. Two patients in CR after BMT remained with persistent thrombocytopenia and/or anemia. Following variThe introduction of new therapeutic agents and strategies for ous therapeutic regimens, eight patients achieved CR (Nos 1-the treatment of CLL has increased the proportion of patients 8), 11 nPR and two PR (Nos 9-21). that achieve complete remission (CR). [1] [2] [3] [4] [5] [6] [7] [8] This may result in Eleven peripheral blood and 10 bone marrow samples from changes in the natural history of the disease. 9, 10 The possibility healthy donors (age 23-50 years) were used to establish referof achieving CR has increased the need for developing accurence values for the percentage of CD5 + B lymphocytes and ate evaluation methods to monitor response to therapy as this the quantitative expression of CD5 and CD19. may have management implications. 3, 11, 12 Flow cytometry has been widely used to detect minimal residual disease (MRD) in Immunostaining acute leukemia 13 and only more recently in chronic lymphoid disorders. 11, 14, 15 In all these studies, the detection of the Mononuclear cells were isolated from fresh heparinized perresidual malignant population by flow cytometry is mainly ipheral blood and bone marrow samples by density gradient based on the presence of aberrant phenotypes and/or quanticentrifugation with Lymphoprep (Nycomed, Oslo, Norway) tative abnormalities of antigen expression. [16] [17] [18] [19] [20] [21] and washed three times in Hank's balanced salt solution. A CLL has a distinct B cell marker profile characterized by total of 1 × 10 6 cells were used per test. Fifty microliters of 2% weak surface immunoglobulin and expression of CD5. 22 The AB serum was added to each tube prior to incubation with CD5 antigen is only expressed in a small percentage of normal the monoclonal antibody (McAb). Double-labelling immunoblood and bone marrow B lymphocytes, 23 therefore the staining was performed using CD5-FITC and CD19-RD1, for phenotype of CLL can be exploited to detect MRD. We have 15 min at room temperature. McAbs of the same IgG subclass investigated the clinical significance of detecting MRD in 21 were used as negative controls in all the experiments. After patients with CLL in CR or partial remission (PR) by using douincubation, cells were washed three times with phosphateble labelling with CD5/CD19 and estimating quantitatively the buffered solution (PBS)/azide, resuspended in 0.5 ml Isoton number of molecules per cell.
(Coulter, Hialeah, FL, USA) and analyzed on the flow cytometer. 26 The methodology applied has been previously described by Farahat et al. 27 The QuickCal (Sigma) software Normal samples:
Results of the analysis of normal samples are shown in Table 2 . Based on these data, a percentage of is designed to construct a calibration curve for each specific reagent and derive ABC values for the cells under study. Table 2 Immunological evaluation in normal controls son, San José, CA, USA). Standard microbeads labelled with CD4-FITC and CD8-PE were used to set the compensation. 
PE (Leu-2a) (Becton Dickinson).
Analysis of residual disease in CLL by flow cytometry E Cabezudo et al 1911 Table 3 Immunological evaluation in CLL patients in CR CD5 and CD19 antigen density in normal controls
The quantitative evaluation of CD5 and CD19 in normal
samples is shown in Table 5 and illustrated in Figure 1a . The analysis of CD5 and CD19 densities in BM samples by quanti- higher in CLL samples than in normal B lymphocytes (Table 5 Table 3 for patients in CR and in Table 4 Table 4 Immunological evaluation in CLL patients in nPR and PR using this method only two patients (Nos 2 and 4) rather than five were in immunological remission.
Correlation with outcome five nPR patients and one PR. The two patients in immunologtive in detecting MRD and offers the advantages of low cost, speed and absence of false positive results. Because CLL cells ical remission continue with no evidence of relapse at 13 and 33 months after BMT, whilst two of the remaining six CR coexpress CD5/CD19, double immunostaining and quantitative flow cytometry can exploit the differences in expression patients with MRD by flow cytometry relapsed. The third BMT patient (No. 6) with residual disease by flow cytometry was of these two membrane antigens by comparison with normal samples. in CR 3 months after the procedure. All patients are alive at the time of this report.
There have only been few studies documenting MRD by flow cytometry in CLL, with the number of cases in immunological remission ranging from 10 to 80%. The techniques used included double labelling with CD5 and a panB McAb Discussion and/or assessment of the K/L ratio. 11, 14, 15, 30 Differences among these studies might be related to: (1) variability of the criteria There have been a number of reports investigating MRD in CLL, either by molecular or flow cytometry techniques. The to define CR, as some of the reports did not include BM histology; (2) variable criteria defining 'immunological level of detection of residual leukemic cells using molecular techniques ranges from 1 to 0.0001% depending whether remission'; and (3) sensitivity of the method. In our study, we have shown that all cases in nPR and PR and six out of eight Southern blot or the polymerase chain reaction (PCR) are applied. 12, 28 The level of detection by flow cytometry has patients considered in CR by bone marrow biopsy did have leukemic cells detectable by flow cytometry. Although we improved from 1%, if only clonality assessment is carried out by the K/L ratio, to 0.001% if quantitative analysis is perforonly investigated 10 out of the 21 patients by the quantitative method, there was good correlation overall between these med. 14, 15, 29 Therefore flow cytometry appears to be very sensi-Quantitative evaluation of BM samples seems to be less useful than that of peripheral blood due to the wide distribution of values founded in normal controls. This may relate to the staining with CD19 of mature lymphocytes and immature precursors. 17 Selection of the B cell population with a McAb not present in B precursors might overcome this problem.
Our study has also shown that persistence of MRD assessed by flow cytometry may predict time to progression. Neither of the two patients in immunological remission relapsed within a follow-up of 13 and 33 months, whilst two of the remaining six CR patients who had positive flow cytometry relapsed. BMT seems to be the only procedure, according to our results, that can achieve immunological remission. Differences in overall survival are however difficult to evaluate due to the short follow-up in the majority of series, including the present one.
Following BMT (autologous or allogeneic) for the treatment of hematological and non-hematological malignancies, most circulating B cells have been reported to express CD5, and residual leukemic cells in CLL patients after BMT, that could not be achieved with conventional flow cytometry as shown in one of the patients (No. 6).
In conclusion, we have demonstrated here that both double labelling with CD5/CD19 and quantitation of these antigens by flow cytometry are sensitive methods for detecting MRD in CLL, are useful to monitor disease status and therefore to assess the effectiveness of therapeutic strategies. of CD19.
